Published in Clin Sci (Lond) on March 01, 2002
Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol (2006) 0.90
Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice. PLoS One (2012) 0.85
Plasma serotonin, pulmonary hypertension and bronchial asthma. Clin Sci (Lond) (2002) 0.75
Noninvasive ventilation for the management of pulmonary hypertension associated with congenital heart disease in children. Pediatr Cardiol (2004) 0.75
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest (2009) 2.02
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med (2002) 1.39
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med (2010) 1.15
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (2011) 1.09
Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.06
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.01
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation (2003) 1.00
cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 1.00
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res (2006) 1.00
Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J (2012) 0.98
Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther (2008) 0.97
Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem (2004) 0.96
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse (2011) 0.95
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One (2012) 0.94
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.93
Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics (2006) 0.91
Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med (2002) 0.91
Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol (2002) 0.90
Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest (2011) 0.88
Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res (2010) 0.86
Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ (2012) 0.86
Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ (2013) 0.85
Advancing clinical trial design in pulmonary hypertension. Pulm Circ (2013) 0.84
Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med (2010) 0.84
Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation (2014) 0.84
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol (2002) 0.82
Genome-wide scan for premature hypertension supports linkage to chromosome 2 in a large Kyrgyz family. Hypertension (2006) 0.82
The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol (2011) 0.81
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res (2005) 0.81
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir Res (2011) 0.81
Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 0.80
Clinical, ethical and financial implications of incidental imaging findings: experience from a phase I trial in healthy elderly volunteers. PLoS One (2012) 0.80
Hypoxia amplifies the proliferative capacity of distal human pulmonary artery smooth-muscle cells. Chest (2005) 0.80
Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford) (2013) 0.79
Regulating cell-based regenerative medicine: the challenges ahead. Regen Med (2014) 0.78
Pulmonary hypertension: biomarkers. Handb Exp Pharmacol (2013) 0.78
Cannabis and cannabis-based medicines: potential benefits and risks to health. Clin Med (2006) 0.78
Emerging therapies for pulmonary arterial hypertension. Expert Opin Investig Drugs (2007) 0.77
[Definitions and diagnosis of pulmonary hypertension]. Turk Kardiyol Dern Ars (2014) 0.77
Update in pulmonary vascular diseases 2012. Am J Respir Crit Care Med (2013) 0.76
Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handb Exp Pharmacol (2013) 0.76
Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulm Circ (2013) 0.76
Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing? Eur Heart J (2003) 0.76
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 0.75
Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”. Circulation (2013) 0.75
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol (2010) 0.75
Autoradiography of enzymes, second messenger systems, and ion channels. Methods Mol Biol (2005) 0.75